Beating a dead horse: Dopamine and Parkinson disease

Neurology

Volumn 69, Issue 17, 2007, Pages 1701-1711

  Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENZODIAZEPINE; CLONAZEPAM; DOPAMINE; LEVODOPA; OXIDOPAMINE; ANTIPARKINSON AGENT;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONSTIPATION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG MEGADOSE; DYSAUTONOMIA; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARASOMNIA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REM SLEEP; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TOPOGRAPHY; TRANSPLANTATION; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; BRAIN; BRAIN TRANSPLANTATION; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SMELLING DISORDER;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; BRAIN TISSUE TRANSPLANTATION; CONSTIPATION; DEEP BRAIN STIMULATION; DOPAMINE; HUMANS; LEVODOPA; OLFACTION DISORDERS; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER;

EID: 36048989265     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000296942.14309.4a     Document Type: Review

References (126)

1. Carlsson A, Falck B, Fuxe K, Hillarp N-A. Cellular localization of brain monoamines. Acta Physiol Scand 1962;56 (suppl 196):1-28.
2. Anden NE, Carlsson A, Dahlstrom A, Fuxe K, Hillarp N-A, Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci 1964;3: 523-530.
3. Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system: IV. Distribution of monoamine nerve terminals in the central nervous system. Acta Physiol Scand 1965;64 (suppl 247):39-85.
4. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959;11:490-493.
5. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with l-dopa. N Engl J Med 1969;280:337-345.
6. Sweet RD, Mc Dowell FH. Five years' treatment of Parkinson's disease with levodopa: therapeutic results and survival of 100 patients. Ann Intern Med 1975;83: 456-463.
7. Diamond SG, Markham CH. Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J Neural Transm 1976;38:259-269.
8. Zumstein H, Siegfried J. Mortality among Parkinson patients treated with l-dopa combined with a decarboxylase inhibitor. Eur Neurol 1976;14:321-327.
9. Martilla RJ, Rinne UK, Siirtola T, Sonninen V. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 1977;216:147-153.
10. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-118.
11. Hoehn MMM. Parkinson's disease: progression and mortality. Adv Neurol 1986;45:457-461.
12. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43: 1918-1926.
13. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40 (suppl 3):32-37.
14. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
15. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
16. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203.
17. Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000;157:1439-1445.
18. Ambani LM, Van-Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 1975;32:114-118.
19. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-310.
20. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
21. Youdim MB, Ben-Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 1989;126:47-54.
22. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435.
23. Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
24. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 2006;545:39-50.
25. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001;24:347-353.
26. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999;9:147-163.
27. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002;52:448-457.
28. Ahlskog JE, Uitti RJ, Low PA, et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 1995;10:566-573.
29. Gibb WRG, Fearnley JM, Lees AJ. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. In: Streifler MB, Korczyn AD, Melamed E, Youdim MB, eds. Parkinson's disease: Anatomy, pathology and therapy. New York: Raven Press, 1990:31-34.
30. Gibb WRG. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291.
31. Wakabayashi K, Mori F, Takahashi H. Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson's disease. Parkinsonism Relat Disord 2006;12 (suppl 2):S92-S98.
32. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990; 27:373-385.
33. Eadie MJ. The pathology of certain medullary nuclei in parkinsonism. Brain 1963;86:781-792.
34. Gai WP, Blumbergs PC, Geffen LB, Blessing WW. Age-related loss of dorsal vagal neurons in Parkinson's disease. Neurology 1992;42:2106-2111.
35. Saper CB, Sorrentino DM, German DC, de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and Parkinson's disease. Ann Neurol 1991;29:577-584.
36. Halliday GM, Ophof A, Broe M, et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128 (pt 11):2654-2664.
37. Fedorow H, Pickford R, Kettle E, et al. Investigation of the lipid component of neuromelanin. J Neural Transm 2006;113:735-739.
38. Han S-K, Mytilineou C, Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
39. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408.
40. Clement M-V, Long LH, Ramalingam J, Halliwell B. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 2002;81:414-421.
41. Muller T, Hefter H, Hueber R, et al. Is levodopa toxic? J Neurol 2004;251 (suppl 6):VI/44-VI/46.
42. Fahn S, Parkinson-Study-Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252 (suppl 4):IV37-IV42.
43. Parkinson-Study-Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351: 2498-2508.
44. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60: 381-389.
45. Albin RL, Frey KA. Initial agonist treatment of Parkinson's disease: a critique. Neurology 2003;60:390-394.
46. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
47. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43:561-575.
48. Fornai F, Battaglia G, Gesi M, et al. Time-course and dose-response study on the effects of chronic l-dopa administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res 2000;887:110-117.
49. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001;16: 424-434.
50. Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomolgus monkeys. J Neural Transm 2002;109:53-67.
51. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003;304:792-800.
52. Ferrario JE, Delfino MA, Stefano AV, et al. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci Res 2003;47:431-436.
53. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of l-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31: 1194-1195.
54. Blunt SB, Jenner P, Marsden CD. Suppressive effect of l-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurontoxin, 6-hydroxydopamine. Mov Disord 1993;8:129-133.
55. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
56. Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to nondegenerating substantia nigra cells? Clinical evidence. Neurology 1996;46 (suppl):A371.
57. Sedel F, Ribeiro MJ, Remy P, Blau N, Saudubray JM, Agid Y. Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia. Neurology 2006;67:2243-2245.
58. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986;19:365-372.
59. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
60. Yahr MD, Wolf A, Antunes J-L, Miyoshi K, Duffy P. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972 ;22 (suppl):56-71.
61. Huisman E, Uylings HBM, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 2004;19:571-579.
62. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000;356:44-45.
63. Olanow CW, Hauser R, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
64. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999;14:911-913.
65. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-982.
66. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
67. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211.
68. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318: 121-134.
69. Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 2004;63:742-749.
70. Klos KJ, Ahlskog JE, Josephs KA, et al. Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 2006; 66:1100-1102.
71. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32:284-295.
72. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
73. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behavior disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
74. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996;46: 388-393.
75. Sastre JP, Sakai K, Jouvet M. Bilateral lesions of the dorso-lateral pontine tegmentum II: effect upon muscle atonia. Sleep Res 1978;7:44.
76. Hendricks JC, Morrison AR, Mann GL. Different behaviors during paradoxical sleep without atonia depend on pontine lesion site. Brain Res 1982;239:81-105.
77. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 2006;441: 589-594.
78. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology 2006;67:742-747.
79. Jacobs BL. Single unit activity of locus coeruleus neurons in behaving animals. Prog Neurobiol 1986;27: 183-194.
80. Uchiyama M, Isse K, Tanaka K, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 1995;45:709-712.
81. Boeve BF, Dickson DW, Olson EJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 2007;8:60-64.
82. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:138-142.
83. Roth J, Radil T, Ruzicka E, Jech R, Tichy J. Apomorphine does not influence olfactory thresholds in Parkinson's disease. Functional Neurol 1998;13:99-103.
84. Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 1992;32:97-100.
85. Ross W, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk of future Parkinson's disease. Mov Disord 2005;20(suppl 10):S129-S130.
86. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006;21:2062-2067.
87. Montgomery EB Jr, Baker KB, Lyons K, Koller WC. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology 1999; 52:757-762.
88. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
89. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128 (pt 1):126-137.
90. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006;66:845-851.
91. Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center. J Clin Gastroenterol 1994; 19:11-16.
92. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
93. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114 (pt 5):2283-2301.
94. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000;247 (suppl 2):II/11-II/18.
95. Bonnet A-M, Loria Y, Saint-Hilaire M-H, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542.
96. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
97. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
98. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
99. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005;57:82-91.
100. Dickson DW, Uchikado H, Klos KJ, Josephs KA, Boeve BF, Ahlskog JE. A critical review of the Braak staging scheme for Parkinson's disease. Mov Disord 2006;21 (suppl 15):S559.
101. Ahlskog JE. The Parkinson's disease treatment book: Partnering with your doctor to get the most from your medications. New York: Oxford University Press, 2005.
102. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
103. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
104. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-344.
105. Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord 2006;21 (suppl 14):S171-S96.
106. Kopell BH, Rezai AR, Chang JW, Vitek JL. Anatomy and physiology of the basal ganglia: implications for deep brain stimulation for Parkinson's disease. Mov Disord 2006;21 (suppl 14):S238-S246.
107. Welter ML, Houeto JL, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002;125 (pt 3):575-583.
108. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21 (suppl 14):S290-S304.
109. Hilker R, Voges J, Ghaemi M, et al. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord 2003;18:41-48.
110. Strafella AP, Sadikot AF, Dagher A. Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease. Neuroreport 2003;14:1287-1289.
111. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 2002;77:918-925.
112. Stover NP, Bakay RA, Subramanian T, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 2005;62:1833-1837.
113. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000;54:1042-1050.
114. Dass B, Olanow CW, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology 2006;66 (suppl 4):S89-S103.
115. Snyder BJ, Olanow CW. Stem cell treatment for Parkinson's disease: an update for 2005. Curr Opin Neurol 2005;18:376-385.
116. Correia AS, Anisimov SV, Li JY, Brundin P. Stem cell-based therapy for Parkinson's disease. Ann Med 2005; 37:487-498.
117. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
118. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
119. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 2005;28:86-92.
120. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996;71:659-670.
121. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005;20:271-282.
122. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55:761-765.
123. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006;313: 324-328.
124. Glatt C, Almonte M, Taylor T, Edwards RH, Freimer N, Tanner C. Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease. Mov Disord 2006;21:426-427.
125. Angell M. The truth about the drug companies: How they deceive us and what to do about it. New York: Random House, 2004.
126. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007;22:1-9.